Development services for minimally invasive glaucoma surgery (MIGS) device

progression of glaucoma, with the ability to regulate pressure post insertion. The development scope, estimated to about 2 years of development, includes optimising the stent design using in sil billiard modelling, prototyping, and in vitro testing with ocular models and extracted pig eyes. Manufact

uring will involve precision techniques such as microscale injection moulding and extrusion, ensuring the production of a batch that meets the standards for preclinical testing. Approximately 100 units are planned for manufacturing to suppo